4月4日 - ** 基因疗法生产商Sarepta Therapeutics SRPT.O股价下跌4.2%，至56.17美元
** Sarepta Therapeutics公司称， (link)，该公司暂时停止了三项测试其治疗杜兴氏肌肉萎缩症的基因疗法Elevidys的试验，因为欧盟监管机构正在审查上个月一名接受其基因疗法的患者的死亡事件。
** 该公司称，一个独立委员会周四召开会议，认为该疗法的效益-风险分析 "仍然有利于在暂停的临床试验中继续给药"。
** 该公司和合作伙伴罗氏公司ROG.S.将应欧盟监管机构的要求在一周内提交这一信息
** 截至上日收盘，SRPT股价累计下跌55.1%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.